丹香冠心注射液联合替格瑞洛和吲哚布芬治疗心肌梗死患者的效果观察  

Effect of Danxiang Guanxin Injection Combined with Ticagrelor and Indobuprofen in the Treatment of Patients with Myocardial Infarction

作　　者：廖振琦 刘克强 LIAO Zhenqi;LIU Keqiang(Department of Cardiovascular Medicine of integrated ChiMese and Western Medicine,Ganxian District People’s Hospital Ganzhou 341000,China;Department of Cardiovascular Medicine,Ganxian District People’s Hospital,Ganzhou 341000,China)

机构地区：[1]江西省赣州市赣县区人民医院中西医结合心血管内科,江西赣州341000 [2]江西省赣州市赣县区人民医院心血管内科,江西赣州341000

出　　处：《中国伤残医学》2024年第19期45-49,共5页Chinese Journal of Trauma and Disability Medicine

摘　　要：目的:观察丹香冠心注射液联合替格瑞洛、吲哚布芬在心肌梗死(MI)患者中的应用效果。方法:选取2023年3月-2024年2月赣县区人民医院收治的118例MI患者为研究对象,随机分为对照组和研究组,各59例。对照组采用替格瑞洛和吲哚布芬治疗,研究组在对照组基础上联合丹香冠心注射液治疗。比较两组临床疗效、冠脉血流情况、心功能指标、血清淀粉样蛋白A1(SAA1)、可溶性白细胞分化抗原40配体(sCD40L)、可溶性生长刺激表达基因2蛋白(sST2)水平和不良反应发生情况。结果:研究组治疗总有效率为94.92%,高于对照组的83.05%,差异有统计学意义(P<0.05)。治疗后,两组左前降支舒张期峰流速(DPV)、收缩期峰流速(SPV)、冠脉血流储备(CFVR)均较治疗前高,且研究组均较对照组高,差异均有统计学意义(P<0.05)。治疗后,两组心输出量(CO)、心排血指数(CI)、左室射血分数(LVEF)水平均较治疗前高,左室收缩末期内径(LVESD)水平较治疗前低,且研究组CI、CO、LVEF水平均较对照组高,LVESD水平较对照组低,差异均有统计学意义(P<0.05)。治疗后,两组血清SAA1、sCD40L、sST2水平均较治疗前低,且研究组均较对照组低(P<0.05),差异均有统计学意义(P<0.05)。研究组的不良反应发生率为16.95%,相较于对照组的8.47%,差异无统计学意义(P>0.05)。结论:丹香冠心注射液联合替格瑞洛和吲哚布芬治疗MI患者,效果明显,可改善患者冠脉血流,增强心功能,降低血清SAA1、sCD40L、sST2水平,安全性高。Objective:To observe the effect of Danxiang Guanxin Injection combined with Ticagrelor and Indobuprofen in patients with myocardial infarction(MI).Methods:A total of 118 patients with MI admitted in Ganxian District People’s Hospital from March 2023 to February 2024 were selected as the study objects,and randomly divided into a control group and a study group,with 59 cases in each group.The control group was treated with Ticagrelor and Indobuprofen,and the study group was treated with Danxiang Guanxin Injection based on the control group.The clinical efficacy,coronary blood flow,cardiac function indexes,serum amyloid A1(SAA1),soluble leukocyte differentiation antigen 40 ligand(sCD40L),soluble growth stimulation-expressed gene 2 protein(sST2)and the occurrence of adverse reactions were compared between the two groups.Results:The total effective rate of the study group was 94.92%,which was higher than 83.05%of the control group,the difference was statistically significant(P<0.05).After treatment,the left anterior descending branch diastolic peak velocity(DPV),systolic peak velocity(SPV)and coronary flow reserve(CFVR)in both groups were higher than before treatment,and the study group were higher than the control group,the differences were statistically significant(P<0.05).After treatment,the levels of cardiac output(CO),cardiac output index(CI)and left ventricular ejection fraction(LVEF)in both groups were higher than before treatment,and the level of left ventricular end-systolic inner diameter(LVESD)was lower than before treatment,and the levels of CI,CO and LVEF in the study group were higher than those in the control group,and the level of LVESD was lower than that in the control group,the differences were statistically significant(P<0.05).After treatment,serum levels of SAA1,sCD40L and sST2 in two groups were lower than before treatment,and the study group was lower than the control group,with statistical significance(P<0.05).The incidence of adverse reactions in the study group was 16.95%,compared with 8.47

关 键 词：心肌梗死 丹香冠心注射液 替格瑞洛 吲哚布芬 冠脉血流 心功能 

分 类 号：R542.2[医药卫生—心血管疾病]